Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms:Proof of principle in phenylketonuria mice by van Vliet, Danique et al.
  
 University of Groningen
Large neutral amino acid supplementation exerts its effect through three synergistic
mechanisms
van Vliet, Danique; Bruinenberg, Vibeke M.; Mazzola, Priscila N.; van Faassen, Martijn H. J.
R.; de Blaauw, Pim; Kema, Ido P.; Heiner-Fokkema, M. Rebecca; van Anholt, Rogier D.; van





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Vliet, D., Bruinenberg, V. M., Mazzola, P. N., van Faassen, M. H. J. R., de Blaauw, P., Kema, I. P., ...
van Spronsen, F. J. (2015). Large neutral amino acid supplementation exerts its effect through three
synergistic mechanisms: Proof of principle in phenylketonuria mice. PLoS ONE, 10(12), [e0143833].
https://doi.org/10.1371/journal.pone.0143833
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
RESEARCH ARTICLE
Large Neutral Amino Acid Supplementation
Exerts Its Effect through Three Synergistic
Mechanisms: Proof of Principle in
Phenylketonuria Mice
Danique van Vliet1,2, Vibeke M. Bruinenberg2, Priscila N. Mazzola1,2, Martijn H. J. R. van
Faassen3, Pim de Blaauw3, Ido P. Kema3, M. Rebecca Heiner-Fokkema3, Rogier D. van
Anholt4, Eddy A. van der Zee2, Francjan J. van Spronsen1*
1 University of Groningen, University Medical Center Groningen, Beatrix Children’s Hospital, Groningen, The
Netherlands, 2 University of Groningen, Center of Behavior and Neurosciences, Department of Molecular
Neurobiology, Groningen, The Netherlands, 3 University of Groningen, University Medical Center





Phenylketonuria (PKU) was the first disorder in which severe neurocognitive dysfunction
could be prevented by dietary treatment. However, despite this effect, neuropsychological
outcome in PKU still remains suboptimal and the phenylalanine-restricted diet is very
demanding. To improve neuropsychological outcome and relieve the dietary restrictions for
PKU patients, supplementation of large neutral amino acids (LNAA) is suggested as alter-
native treatment strategy that might correct all brain biochemical disturbances caused by
high blood phenylalanine, and thereby improve neurocognitive functioning.
Objective
As a proof-of-principle, this study aimed to investigate all hypothesized biochemical treat-
ment objectives of LNAA supplementation (normalizing brain phenylalanine, non-phenylal-
anine LNAA, and monoaminergic neurotransmitter concentrations) in PKU mice.
Methods
C57Bl/6 Pah-enu2 (PKU) mice and wild-type mice received a LNAA supplemented diet, an
isonitrogenic/isocaloric high-protein control diet, or normal chow. After six weeks of dietary
treatment, blood and brain amino acid and monoaminergic neurotransmitter concentrations
were assessed.
Results
In PKU mice, the investigated LNAA supplementation regimen significantly reduced blood
and brain phenylalanine concentrations by 33% and 26%, respectively, compared to normal
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chow (p<0.01), while alleviating brain deficiencies of some but not all supplemented LNAA.
Moreover, LNAA supplementation in PKU mice significantly increased brain serotonin and
norepinephrine concentrations from 35% to 71% and from 57% to 86% of wild-type concen-
trations (p<0.01), respectively, but not brain dopamine concentrations (p = 0.307).
Conclusions
This study shows that LNAA supplementation without dietary phenylalanine restriction in
PKUmice improves brain biochemistry through all three hypothesized biochemical mecha-
nisms. Thereby, these data provide proof-of-concept for LNAA supplementation as a valuable
alternative dietary treatment strategy in PKU. Based on these results, LNAA treatment should
be further optimized for clinical application with regard to the composition and dose of the
LNAA supplement, taking into account all three working mechanisms of LNAA treatment.
Introduction
Phenylketonuria (PKU; OMIM 261600) is the first disorder in which severe neurocognitive
dysfunction could be prevented by dietary treatment. It is caused by a deficient activity of the
hepatic enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1), normally converting phenyl-
alanine (Phe) to tyrosine. If left untreated, classical PKU symptomatology is almost exclusively
restricted to the brain, including severe neurocognitive dysfunction, seizures, and psychiatric
problems, correlating with high blood Phe concentrations [1].
This selective brain vulnerability to high blood Phe concentrations is hypothesized to be
related to the transport characteristics for Phe at the blood-brain barrier (BBB) [2,3]. At the
BBB, the large neutral amino acid transporter 1 (LAT1) is the predominant transport system
for all large neutral amino acids (LNAA), and is saturated for>95% [4]. Combined with the
fact that LAT1 shows a high affinity to Phe, increased blood Phe concentrations strongly
increase brain Phe influx, outcompeting the transport of other LNAA [5–8]. Based on both the
increased Phe and the decreased non-Phe LNAA transport across the BBB, different brain bio-
chemical disturbances underlie brain dysfunction in PKU [3,9]. High brain Phe concentrations
have been found to be neurotoxic and to affect brain metabolism [10–14], while reduced brain
availability of non-Phe LNAA has been related to impaired cerebral protein synthesis [6,15]. In
addition, impaired cerebral monoaminergic neurotransmitter synthesis may result from out-
competed brain uptake of their amino acid precursors tyrosine and tryptophan [16], and/or
from an inhibitory effect of high brain Phe concentrations on tyrosine hydroxylase (TH) and
tryptophan hydroxylase (TPH) [17].
Thus far, blood Phe reduction has been the primary target of treatment in PKU. This can be
accomplished by a severe Phe-restricted diet and, in some patients, by pharmacological treat-
ment with tetrahydrobiopterin. However, early- and continuously treated PKU patients still
show impaired executive functioning and are prone to develop anxiety and depressive symp-
toms [18,19]. Moreover, the Phe-restricted diet is socially demanding and hard to comply with
[20]. Therefore, an alternative pathophysiology-based treatment strategy directly targeting the
brain is required. One such possible treatment strategy includes supplementation of LNAA
(without Phe) that aims to restore the disturbed LNAA transport across the BBB without die-
tary Phe restriction. Based on aforementioned hypotheses on PKU pathophysiology, LNAA
supplementation could serve to: 1) decrease brain Phe, 2) increase brain non-Phe LNAA, and/
or 3) increase brain monoaminergic neurotransmitter concentrations [21].
LNAA Supplementation in PKUMice
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Previous research on LNAA treatment in PKU has primarily focused on brain and blood
Phe reduction as treatment objective [22–28]. In addition, LNAA supplementation in PKU
patients was recently found to increase blood and urine melatonin concentrations, which
might reflect increased brain serotonin synthesis [29]. However, not all brain biochemical
treatment objectives have been investigated. In consequence, optimal composition and dosing
of LNAA treatment is currently unknown, limiting its clinical application. As a first step to
develop an optimal LNAA treatment regimen, the aim of the present study was to assess all




To establish a new breeding colony, breeding pairs of C57Bl/6 Pah-enu2mice had been kindly
provided by Prof. B. Thöny from the division of Clinical Chemistry and Biochemistry of the
University Children’s Hospital in Zurich in Switzerland. From heterozygous (+/-) mating,
wild-type (WT, +/+), heterozygous, and PKU (-/-) mice of both sexes were obtained. After
weaning at four weeks of age, genetic characterization was performed by quantitative PCR
analysis on DNA extracted from ear tissue. Animals were housed individually at 21±1°C on a
12-hr light-dark cycle (7:00 am-7:00 pm), and water and AM-II food pellets (Arie Block BV,
Woerden, The Netherlands) were offered ad libitum. In total, 42 WT (21 male, 21 female) and
46 PKU (23 male, 23 female) mice were used. This study was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health (S1 ARRIVE Checklist). The protocol was approved by the Insti-
tutional Animal Care and Use Committee of the University of Groningen (Permit Number:
6504A).
Experimental design
At postnatal day 37, animals were assigned to one of three treatment groups based on genotype
and sex, receiving either normal chow, a high-protein diet, or a LNAA supplemented diet. Die-
tary treatment was continued for six weeks. During the first week of treatment, body weight
and food intake were measured daily, after which body weight and food intake were deter-
mined at weekly intervals. Food intake was manually assessed by the difference between food
given and left on the cages’ tops using a scale. Spilled food was not measured because it has
been shown to represent less than 0.1 g/day/mouse [30]. After six weeks of dietary treatment,
animals were euthanized by combined heart puncture and decapitation under inhalation-anes-
thetics with isoflurane 2–3 hours after the beginning of the light phase.
Experimental diets
The basal diet during the experiment was based on the composition of AIN-93M [31], which
was also administered in unadjusted form to the untreated control group (normal chow). The
experimental LNAA diet was based on the LNAA regimen as used in the study by Pietz et al.
[26]. It was produced by adding LNAA to the basal diet at the expense of cornstarch on a
weight-for-weight basis. The added amount of LNAA was equal to the amount of (natural)
protein in the basal diet, in effect doubling the amount of protein/amino acids in the LNAA
supplemented diet. The LNAA added in the LNAA supplemented diet included equal amounts
of l-tyrosine, l-tryptophan, l-valine, l-isoleucine, l-leucine, l-methionine, and l-histidine. To
control for the extra amount of protein in the LNAA supplemented diet, a high-protein control
LNAA Supplementation in PKUMice
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diet was included. This high-protein diet was produced by adding extra casein to the AIN-93M
diet at the expense of cornstarch on a weight-for-weight basis, and was calculated to result in
an isonitrogenic and isocaloric control diet for the experimental LNAA diet. Diets were pre-
pared by Research Diet Services B.V. (Wijk bij Duurstede, The Netherlands).
Biochemical analyses
To obtain plasma and brain material for biochemical analyses, blood was collected by heart
puncture and whole brains were removed. Blood was centrifuged at 1500 g for 10 min and
plasma was collected and stored at -80°C until further analysis. The cerebrum was snap frozen
in liquid nitrogen and stored at -80°C until further preparation. Frozen cerebrum was crushed
in liquid nitrogen and divided into aliquots. Frozen brain powder for amino acid measure-
ments was processed to 20% (weight: volume (w:v)) homogenates in phosphate-buffered saline
(pH 7.4), and for tryptophan, indole and catecholamine measurements to 2% (w:v) homoge-
nates in acetic acid (0.08 M). Brain homogenates were sonified on ice at 11–12 W. Next, sam-
ples were centrifuged at 800 rcf for 10 min (4°C), and the supernatant/internatant was put on
ice to be used for further analysis.
For brain amino acid (except for tryptophan) measurements, norleucine in sulfosalicylic
acid was added as an internal standard to the 20% brain homogenate (1:1, v:v). Samples were
vortexed and centrifuged at 20.800 rcf for 4 min. Plasma amino acid measurements were per-
formed according to the same method, using 50 μl plasma instead of 20% brain homogenate.
Amino acid concentrations were measured with a method based on ion exchange chromatog-
raphy with post column derivatization with Ninhydrin on a Biochrom 30+ analyser (Pharma-
cia Biotech, Cambridge, UK).
For tryptophan and monoaminergic neurotransmitter measurements, an anti-oxidative
solution was prepared in demineralised water (0.4 g/l ascorbic acid and 1.616 g/l ethylenedi-
aminetetraacetic acid). For tryptophan and indole measurements, 25 μl of the anti-oxidative
solution was added to 25 μl of the 2% brain homogenate. For catecholamine measurements,
40 μl of the anti-oxidative solution was added to 10 μl of the 2% brain homogenate. Plasma
tryptophan measurements were performed using 25 μl plasma instead of 2% brain homoge-
nate. Analysis of tryptophan and monoaminergic neurotransmitter concentrations was per-
formed using liquid chromatography in combination with isotope dilution mass spectrometry,
essentially as described by Van de Merbel et al. [32].
Statistical analyses
Statistical analyses were performed using the software IBM SPSS Statistics for Windows, Ver-
sion 22.0. (Armonk, NY: IBM Corp.). Data of the one animal that was euthanized preterm,
were excluded from analyses. All tests were performed two-sided at a significance level of α =
0.05.
Analyses on brain and blood biochemistry as well as on weekly food intake (per g body
weight) were performed by two-way ANOVA with genotype and diet as independent variables.
In case of not normally distributed data (assessed by Shapiro-Wilk test) or unequal variances
(assessed by Levene’s test), analyses were performed on log-transformed data. If the interaction
between genotype and diet and/or a main effect of diet was found to be significant, data were
further analyzed by one-way ANOVA and Tukey’s post-hoc tests for PKU and WTmice
separately.
The effect of dietary treatment on body weight was analyzed for WT and PKU male and
female mice separately by repeated-measures ANOVA with one between factor (diet, three
LNAA Supplementation in PKUMice
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levels: normal chow, high-protein diet, and LNAA diet) and one within factor (time, 7 levels: 0,
1, 2, 3, 4, 5, and 6 weeks) and Tukey’s post-hoc analysis.
To investigate whether brain Phe concentrations in PKU mice were primarily determined
by blood Phe concentrations or by dietary treatment, multiple linear regression analysis was
performed with blood Phe concentrations and dietary treatment as independent variables.
Data are expressed as mean ± standard deviation (SD).
Results
Food and LNAA intake
Amino acid contents of the different diets are presented in Table 1.
Weekly food intake (expressed as g food/g body weight/week), as shown in Fig 1, decreased
during the first weeks for all treatment groups, stabilizing in the later weeks of dietary treat-
ment. In both the fifth and sixth week of dietary treatment, two-way ANOVA analyses showed
a significant main effect of genotype on food intake (p<0.01). Moreover, in both weeks, a sig-
nificant main effect of dietary treatment (p<0.01), and a significant interaction between geno-
type and dietary treatment on food intake was observed (p<0.01 for week 5, p<0.05 for week
6). In PKUmice, food intake in both weeks was lower on high-protein diet than on normal
chow (p<0.05), while being even lower on LNAA supplemented diet (p<0.01). In WT mice,
food intake in both weeks did not significantly differ for any of the dietary treatments
(p = 0.376 and p = 0.322). Based on the weekly food intakes and amino acid contents of the
Table 1. Nutritional content of the experimental diets (g/kg diet).
Nutritional content* normal chow LNAA diet high-protein diet
Carbohydrates 674 550 551
Fat 41 41 41
Dietary ﬁbre 50 50 50
Protein 124 248 248
Amino acids**
LNAA L-Phenylalanine 6.0 6.1 (0.1) 12.2 (6.2)
L-Tyrosine 4.8 20.1 (15.3) 12.1 (7.3)
L-Valine 7.4 25.0 (17.6) 15.9 (8.5)
L-Isoleucine 5.9 22.9 (17.0) 12.4 (6.4)
L-Leucine 10.9 28.0 (17.1) 23.1 (12.2)
L-Methionine 3.0 19.7 (16.7) 6.9 (3.9)
L-Histidine 3.2 19.0 (15.8) 6.8 (3.5)
L-Threonine 5.3 5.7 (0.3) 11.3 (5.9)
non-LNAA L-Aspartic acid 9.3 9.7 (0.4) 19.4 (10.1)
L-Serine 7.7 7.9 (0.2) 15.8 (8.1)
L-Glutamic acid 28.2 29.9 (1.7) 59.6 (31.4)
Glycine 2.7 2.7 (0.0) 5.2 (2.5)
L-Alanine 3.9 4.2 (0.3) 8.2 (4.3)
L-Lysine 9.1 9.9 (0.8) 19.5 (10.4)
L-Arginine 4.2 4.7 (0.5) 9.5 (5.3)
Contents are not shown for L-Tryptophan, L-Proline, and L-cyst(e)ine, as these were not measured due to technical limitations. Differences with LNAA
contents of normal chow are stated in brackets. LNAA, large neutral amino acid.
*Mineral and vitamin premixes were also included in accordance with the composition of the AIN93M diet [30].
**Dietary contents as measured in samples of prepared food pellets.
doi:10.1371/journal.pone.0143833.t001
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different diets, mean daily intakes of individual LNAA during the six week dietary treatment
were calculated for all experimental groups as shown in the S1 Table.
Body weight and general health
At initiation of treatment, body weight of PKU mice (male 13.7 ± 3.6 g; female: 12.8 ± 2.1 g)
was lower than of WT mice (male 18.9 ± 1.5 g; female: 15.6 ± 1.8 g), but did not significantly
differ between dietary groups in PKU nor WTmice. Body weight curves during treatment were
significantly lower for WT female mice on LNAA supplemented diet compared to either nor-
mal chow (p<0.05) or high-protein diet (p<0.01), but did not significantly differ between die-
tary treatments for WT male (p = 0.485) and PKU male or PKU female mice (p = 0.397 and
p = 0.343) (Fig 2).
During the experiment, one animal (WT female on LNAA supplemented diet) was eutha-
nized on the 19th day after inclusion, because of too much weight loss. Pathological examina-
tion showed hydrocephalus, which is sometimes found in C57Bl/6 (both WT and PKU) mice.
Plasma amino acids
Plasma concentrations of individual LNAA in PKU and WTmice on control and LNAA sup-
plemented diets are depicted in Fig 3. Two-way ANOVA analyses showed a significant main
effect of genotype on plasma Phe, tyrosine, tryptophan (p<0.01), and threonine concentrations
(p<0.05). In PKU compared to WT mice on normal chow, plasma Phe concentrations were
increased by almost 30-fold. Plasma tyrosine, tryptophan, and threonine concentrations in
PKUmice were reduced to 55%, 77%, and 79%, respectively, of concentrations in WT mice on
normal chow. For other LNAA, no significant main effect of genotype was observed on plasma
concentrations.
A significant main effect of dietary treatment was observed on plasma concentrations of all
LNAA except for threonine (p = 0.073 for threonine; p<0.05 for tyrosine; p<0.01 for all other
LNAA). Moreover, two-way ANOVA analyses showed a significant interaction between geno-
type and dietary treatment on plasma Phe and methionine concentrations (p<0.01 for both).
Fig 1. Weekly food intake for WT (A) and PKU (B) mice on different diets.Numbers of mice on normal chow, LNAA supplemented diet, and high-protein
diet were n = 14, n = 14, and n = 14 for WTmice respectively, while being n = 15, n = 14, and n = 15 for PKUmice. Error bars represent SEM.
doi:10.1371/journal.pone.0143833.g001
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In PKU mice, plasma Phe concentrations on LNAA supplemented diet were significantly
reduced to 67% of concentrations on normal chow (p<0.01), while plasma Phe concentrations
on high-protein diet were significantly higher than on normal chow (p<0.01). In WT mice on
LNAA, plasma Phe concentrations were reduced compared to control diets (p<0.05), but con-
centrations on high-protein diet did not significantly differ from those on normal chow
(p = 0.929). Plasma concentrations of supplemented LNAA were higher on LNAA supplemen-
tation compared to control diets, both in PKU and WTmice, although this did not reach statis-
tical significance for all LNAA.
Plasma concentrations of non-LNAA amino acids in PKU and WTmice on control and
LNAA supplemented diets are presented in S2 Table. In both PKU and WTmice, plasma gly-
cine and lysine concentrations on LNAA supplemented diet were lower compared to control
diets (p<0.05), just not reaching statistical significance for lysine in PKU mice (p = 0.051). In
addition, plasma serine concentrations were lower on LNAA supplementation compared to
control diets in WT mice (p<0.05), but not in PKU mice (p = 0.407).
Brain amino acids
Brain concentrations of individual LNAA in PKU and WTmice on control and LNAA supple-
mented diets are depicted in Fig 4. Two-way ANOVA analyses showed a significant main effect
of genotype on brain concentrations of all LNAA except for methionine (p<0.01 for all LNAA
but methionine, p = 0.523 for methionine). In PKU compared to WTmice on normal chow,
brain Phe concentrations were increased by 8.3-fold. Also, brain histidine concentrations in
PKUmice were elevated to 139% of WT concentrations on normal chow. Brain concentrations
of all other non-Phe LNAA but methionine were reduced in PKUmice on normal chow, rang-
ing from 52% of concentrations in corresponding WT mice for tyrosine to 77% for leucine.
A significant main effect of dietary treatment was observed on brain Phe, tryptophan,
methionine, and threonine concentrations (p<0.01 for all). Moreover, two-way ANOVA
Fig 2. Body weights during the experiment.Mean body weights for A) male and B) female WT (dashed lines) and PKU (solid lines) mice on different diets.
Numbers of mice on normal chow, LNAA supplemented diet, and high-protein diet were n = 14, n = 14, and n = 14 for WTmice respectively, while being
n = 15, n = 14, and n = 15 for PKUmice. Error bars represent SEM.
doi:10.1371/journal.pone.0143833.g002
LNAA Supplementation in PKUMice
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analyses showed a significant interaction between genotype and dietary treatment on brain
Phe, methionine, and histidine concentrations (p<0.01 for Phe and methionine, p<0.05 for
histidine). Brain Phe concentrations in PKU mice on LNAA supplementation were reduced to
74% of concentrations on normal chow (p<0.01), still being 6.1-fold higher when compared to
WT concentrations on normal chow. Brain Phe concentrations in PKUmice on high-protein
diet were higher than in PKUmice on normal chow (p<0.05). Brain tryptophan, histidine, and
methionine concentrations in PKUmice on LNAA supplementation were significantly higher
when compared to PKUmice on normal chow (p<0.05), resulting in concentrations of 100%
and 166% of WT concentrations on normal chow for tryptophan and histidine, and an eleva-
tion by 3.6-fold for methionine. In contrast, brain threonine concentrations in PKUmice on
LNAA supplementation were lower when compared to PKU mice on control diets (p<0.01).
In WT mice, brain Phe concentrations on LNAA supplementation tended to be lower when
compared to normal chow, although this just did not reach statistical significance (p = 0.053).
Similar to PKU mice, brain methionine concentrations were higher, whereas brain threonine
concentrations were lower on LNAA supplementation as compared to control diets (p<0.01
for all).
Brain concentrations of non-LNAA amino acids in PKU and WTmice on control and
LNAA supplemented diets are presented in S3 Table. In both PKU and WTmice, brain serine
Fig 3. Plasma LNAA concentrations. Plasma concentrations of A) phenylalanine, B) tyrosine, C) tryptophan, D) valine, E) isoleucine, F) leucine, G)
methionine, H) histidine, and I) threonine in WT and PKUmice after six weeks of receiving different diets. Numbers of mice on normal chow, LNAA
supplemented diet, and high-protein diet were n = 14, n = 12, and n = 14 for WTmice respectively, while being n = 14, n = 12, and n = 15 for PKUmice.
Untransformed data are expressed as mean ± SEM. * p<0.05; ** p<0.01; § p<0.05 and §§ p<0.01 compared to WTmice on normal chow.
doi:10.1371/journal.pone.0143833.g003
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and glycine concentrations on LNAA supplemented diet were lower compared to control diets
(p<0.05), although this did not reach statistical significance for glycine in PKUmice on LNAA
supplementation compared to high-protein diet (p = 0.064). In addition, in WT mice only,
brain lysine concentrations were lower (p<0.01), whereas brain taurine concentrations were
higher on LNAA supplementation compared to control diets (p<0.05).
Brain monoaminergic neurotransmitters
Brain monoaminergic neurotransmitter and associated metabolite concentrations in PKU and
WTmice are depicted in Fig 5. In the catecholamine pathway, two-way ANOVA analyses
showed significant main effects of genotype on brain dopamine and norepinephrine concentra-
tions (p<0.01 for both). Brain dopamine and norepinephrine concentrations in PKU mice on
normal chow were reduced to 76% and 57%, respectively, of concentrations in WT mice on the
same diet. In the serotonergic pathway, significant main effects of genotype were observed on
brain concentrations of serotonin and its associated metabolite 5-hydroxyindoleacetic acid
(5-HIAA) (p<0.01 for both). Brain serotonin and 5-HIAA concentrations in PKU mice on
Fig 4. Brain LNAA concentrations. Brain concentrations of A) phenylalanine, B) tyrosine, C) tryptophan, D) valine, E) isoleucine, F) leucine, G) methionine,
H) histidine, and I) threonine in WT and PKUmice after six weeks of receiving different diets. Numbers of mice on normal chow, LNAA supplemented diet,
and high-protein diet were n = 13, n = 12, and n = 14 for WTmice respectively, while being n = 14, n = 12, and n = 14 for PKUmice. Untransformed data are
expressed as mean ± SEM. * p<0.05; ** p<0.01; § p<0.05 and §§ p<0.01 compared to WTmice on normal chow.
doi:10.1371/journal.pone.0143833.g004
LNAA Supplementation in PKUMice
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normal chow were decreased to 35% and 26%, respectively, of concentrations in corresponding
WTmice.
Dietary treatment had no significant effect on brain catecholamine or serotonin concentra-
tions in WT mice, while in PKU mice it did. A significant main effect of dietary treatment was
observed on brain catecholamine, serotonin, and 5-HIAA concentrations (p<0.01 for all but
dopamine, p<0.05 for dopamine). Moreover, two-way ANOVA analyses showed a significant
interaction between genotype and dietary treatment on brain norepinephrine, serotonin, and
5-HIAA (p<0.01 for all), but not dopamine concentration (p = 0.766).
In the catecholamine pathway, LNAA supplementation in PKU mice resulted in signifi-
cantly higher brain norepinephrine concentrations compared to normal chow (p<0.01), and
partially restored its deficit to an average of 86% of concentrations in WT mice on normal
chow. In contrast, brain dopamine concentrations did not significantly differ in PKU mice
between the dietary treatments (p = 0.307). In WT mice, no significant differences were
observed between any of the dietary treatments for neither dopamine (p = 0.104) nor norepi-
nephrine (p = 0.283).
In the serotonergic pathway, in PKU mice on LNAA supplementation, both brain serotonin
and 5-HIAA concentrations were significantly increased when compared to control diets
(p<0.01), partially restoring their concentrations to an average of 71% and 67%, respectively,
of concentrations in WT mice on normal chow. In WTmice on LNAA supplementation, brain
serotonin concentrations tended to be higher compared to normal chow (p = 0.051), and brain
5-HIAA concentrations tended to be higher compared to high-protein diet (p = 0.097), but
both did not reach statistical significance.
Relation between plasma and brain Phe
To investigate whether the reduction of brain Phe concentrations on LNAA supplementation in
PKUmice was primarily related to an effect at the BBB or especially related to reduced blood Phe
concentrations, the relationship between blood and brain Phe concentrations was assessed in
PKUmice on LNAA supplementation and control diets (Fig 6). Multiple linear regression analy-
sis showed that brain Phe concentrations in PKUmice were significantly predicted (adjusted
R2 = 0.801, F = 75.525, p<0.01) by both blood Phe concentrations (B = 0.127, SE B = 0.026,
β = 0.521) and LNAA supplemented diet (B = -166.940, SE B = 39.006, β = -0.451). Brain non-
Phe LNAA concentrations in PKUmice on normal chow, LNAA supplementation, and high-
protein diet did not show a clear relationship with either their respective blood concentrations
nor with blood Phe concentrations (data not shown).
Fig 5. Brain monoaminergic neurotransmitter concentrations. Brain concentrations of A) dopamine, B) norepinephrine, C) serotonin in WT and PKU
mice after six weeks of receiving different dietary treatments. Numbers of mice on normal chow, LNAA supplemented diet, and high-protein diet were n = 13,
n = 12, and n = 14 for WTmice respectively, while being n = 15, n = 13, and n = 15 for PKUmice. Untransformed data are expressed as mean ± SEM.
**p<0.01; §§ p<0.01 compared to WTmice on normal chow.
doi:10.1371/journal.pone.0143833.g005
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Relation between brain monoaminergic neurotransmitters and their
precursors
To investigate whether the increase of brain serotonin and norepinephrine on LNAA supple-
mentation in PKU mice was primarily due to (1) increased brain availability of their precur-
sors, or to (2) enhanced conversion of their precursors, brain monoaminergic
neurotransmitters were assessed in relation to their respective (amino acid) precursors (Fig 7).
Two-way ANOVA analyses showed a significant main effect of genotype on ratios of brain
dopamine/tyrosine, norepinephrine/dopamine, and serotonin/tryptophan (p<0.01 for all), but
not norepinephrine/tyrosine concentrations (p = 0.184). Ratios of brain dopamine/tyrosine
were increased, while rations of brain norepinephrine/dopamine and serotonin/tryptophan
concentrations were reduced in PKU compared to WTmice on normal chow.
A significant main effect of dietary treatment was observed on ratios of brain norepineph-
rine/dopamine concentrations only (p<0.01). In addition, two-way ANOVA analyses showed
a significant interaction between genotype and dietary treatment on ratios of brain norepi-
nephrine/dopamine and serotonin/tryptophan concentrations (p<0.01 for both). In PKU mice
on LNAA supplementation, ratios of brain norepinephrine/dopamine were increased com-
pared to control diets (p<0.01). Also, ratios of brain serotonin/tryptophan concentrations in
PKUmice on LNAA supplementation were higher as compared to control diets (p<0.05).
Discussion
This study is the first to investigate all hypothesized biochemical treatment effects of LNAA
supplementation using one LNAA supplementation regimen and a single experimental design.
Besides reducing blood Phe concentrations, the present study showed that LNAA
Fig 6. Plasma versus brain Phe concentrations in PKUmice on different dietary treatments. Relationship between plasma Phe and brain Phe
concentrations in PKUmice on normal chow (n = 13), LNAA supplemented diet (n = 12), and high-protein diet (n = 14).
doi:10.1371/journal.pone.0143833.g006
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supplementation without dietary Phe restriction in PKUmice could directly improve brain
biochemistry through three mechanisms: 1) reducing brain Phe concentrations, 2) attenuating
the brain deficiencies of some, but not all, LNAA, and 3) increasing brain serotonin and nor-
epinephrine, but not dopamine concentrations. Before discussing these results in more detail,
we will first address some methodological issues.
Firstly, the present experiment was performed in Pah-enu2 (PKU) mice, a well-established
model that resembles the genetics, biochemistry and neurobiology of classical PKU in humans.
Biochemically, PKU mice show high blood and brain Phe concentrations in combination with
brain non-Phe LNAA and monoaminergic neurotransmitter deficits that also characterize
human PKU biochemistry. Km-values for LNAA transport at the BBB have not been deter-
mined for (PKU) mice [33]. However, Km-values for individual LNAA as determined in vivo in
rats and in human brain capillaries showed a significant correlation [34], while being approxi-
mately 8–40 times lower for humans than for rats. This could imply that competition between
Phe and non-Phe LNAA for transport across the BBB takes place at lower plasma concentra-
tions in humans than in rats (and maybe mice), so that LNAA supplementation might be even
more effective in PKU patients. One of the important advantages of this PKU mouse model
over clinical studies is the possibility to measure not only Phe (that can be determined in
humans by magnetic resonance spectroscopy (MRS)) but also non-Phe LNAA and monoamin-
ergic neurotransmitter concentrations in brain (that at present cannot be measured by MRS).
Fig 7. Ratios of brain monoaminergic neurotransmitters to precursors. Ratios of brain A) dopamine/tyrosine, B) norepinephrine/tyrosine, C)
norepinephrine/dopamine, and D) serotonin/tryptophan concentrations in WT and PKUmice after six weeks of receiving different dietary treatments.
Numbers of mice on normal chow, LNAA supplemented diet, and high-protein diet were n = 13, n = 12, and n = 14 for WTmice respectively, while being
n = 14, n = 12, and n = 14 for PKUmice. Untransformed data are expressed as mean ± SEM. *p<0.05; **p<0.01; and § p<0.05; §§ p<0.01 compared to WT
mice on normal chow.
doi:10.1371/journal.pone.0143833.g007
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Secondly, the LNAA supplemented diet used was based on the study by Pietz et al. (1999)
that investigated the effect of concomitant LNAA supplementation during an oral Phe chal-
lenge on brain Phe uptake and EEG activity in PKU patients [26]. The LNAA supplementation
regimen used by Pietz et al. consisting of equal amounts (150 mg/kg body weight) of all non-
Phe LNAA except for threonine, in total, approximated the daily dietary protein intake for
adults. To translate this acute regimen for PKU patients to chronic treatment in PKU mice, the
total amount of added LNAA in the present study was equal to the amount of natural protein
in the basal diet. In full accordance with the study by Pietz et al., threonine was not supple-
mented, even though Sanjurjo et al. (2003) have shown threonine supplementation alone
(50 mg/kg/d) reduced blood Phe concentrations by 36% in PKU patients [35].
LNAA supplementation reduces blood Phe concentrations
Although LNAA supplementation is suggested to improve brain metabolism primarily by
restoring the unbalanced LNAA transport at the BBB, LNAA supplementation in PKU mice
was also found to significantly reduce blood Phe concentrations to 67% of concentrations on
normal chow. This is in accordance with previous studies on LNAA supplementation in PKU
mice showing plasma Phe reductions to 47.0–63.5% of concentrations in untreated PKU con-
trols [23,24]. LNAA supplementation has been hypothesized to exert this effect through com-
petition with Phe for uptake at the gut-blood barrier [21], or through increased Phe utilization
due to higher net protein synthesis [21]. In support of this last hypothesis, food intake of PKU
mice during the final weeks of the experiment was significantly lower on LNAA supplemented
diet than on control diets, while body weight did not significantly differ. This may suggest that
LNAA supplementation indeed induced anabolism in PKUmice, thereby demanding a lower
dietary protein (and thus food) intake, and by that contributing to the observed plasma Phe
reduction. As expected, plasma concentrations of supplemented LNAA in PKU mice were all
increased. Surprisingly, however, plasma tyrosine concentrations in PKU mice remained low-
normal on the currently applied LNAA supplemented diet. Even when correcting for the 20%
of the supplemented tyrosine that is assumed not to be absorbed in the gastrointestinal tract
[21], tyrosine intake still was 3.5 times higher in the LNAA supplemented diet compared to
normal chow. Similar to plasma tyrosine concentrations, brain tyrosine concentrations were
not significantly increased on LNAA supplemented diet either, while brain norepinephrine—
the end product of tyrosine-derived neurotransmitter metabolism—was significantly increased
on LNAA supplemented diet. Therefore, a possible explanation might be that all supplemented
tyrosine was used to partly restore the profound brain norepinephrine deficiency, and thereby
did not result in increased plasma and brain tyrosine concentrations.
LNAA supplementation reduces brain Phe concentrations, while
attenuating brain deficiencies of some but not all non-Phe LNAA
In brain, Phe concentrations on LNAA supplementation in PKU mice were significantly
reduced by 26% compared to concentrations on normal chow. This is in good agreement with
previous studies on LNAA supplementation in both PKU patients [25] and mice [24], showing
brain Phe reductions of 20–46%. Moreover, it may well support the finding of a clear competi-
tive effect on Phe transport across the BBB in PKU patients by Pietz et al. (1999) using a com-
parable LNAA supplement [26]. As besides brain Phe, blood Phe concentrations were also
reduced in PKUmice on LNAA supplementation, the question arises whether the reduced
brain Phe concentrations might be due to the reduced plasma Phe concentrations rather than a
direct effect at the BBB level. Multiple linear regression analysis suggests, however, that LNAA
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supplementation reduced brain Phe concentrations in PKUmice through a combined effect of
both plasma Phe reduction and enhanced competition at the BBB.
This is the first time that brain non-Phe LNAA concentrations have been reported in
response to LNAA supplementation in PKU. The LNAA supplementation regimen that was
used, changed most brain non-Phe LNAA concentrations, restoring brain tryptophan in PKU
mice to WT concentrations. Brain methionine concentrations were even significantly increased
by 5.5-fold in PKU mice on LNAA supplementation compared to normal chow, corresponding
with the similarly strong increases in blood. Although the cerebral and systemic effects and
possible toxicity due to these strongly elevated methionine concentrations are not fully under-
stood [36], at least these results warrant against indiscriminate supplementation of methionine
in PKU. Also, brain histidine concentrations in PKUmice were even further increased on
LNAA supplementation. From the fact that histidinaemia, in which brain histidine concentra-
tions are much more increased, is not associated with any brain dysfunction, we may conclude
that this elevation of brain histidine as observed in PKU mice probably does not have clinical
significance [37]. On the other hand, brain concentrations of threonine, which was not
included in the LNAA supplement, were significantly reduced in both PKU andWT mice on
LNAA supplemented diet. This further supports the idea that highly unbalanced LNAA intake
may induce brain deficiencies of some LNAA.
It can be concluded from these results that LNAA supplementation in PKUmice indeed
attenuates brain Phe concentrations and attenuates brain deficiencies of (at least some) non-
Phe LNAA. At the same time, results suggest that the relationships between brain non-Phe
LNAA concentrations and their respective plasma concentrations as well as plasma Phe con-
centrations are complex and differ for each non-Phe LNAA, given the amount of LNAA sup-
plementation used in this study. Development of the optimal LNAA supplementation regimen
that can both effectively reduce brain Phe concentrations and improve brain concentration of
all non-Phe LNAA therefore clearly deserves further research.
LNAA treatment improves brain serotonin and norepinephrine, but not
dopamine, concentrations
Besides its effect on brain LNAA concentrations, LNAA supplementation in PKU mice signifi-
cantly increased brain serotonin from 35% to 71% of concentrations in WT mice. Also, brain
norepinephrine in PKU mice on LNAA supplementation increased from 57% to 86% of con-
centrations in WT mice, whereas brain dopamine concentrations remained unchanged.
Although brain monoaminergic neurotransmitter concentrations in response to LNAA supple-
mentation have not been reported previously, a recent study on LNAA supplementation in
PKU patients showed increased melatonin (a serotonin metabolite) concentrations in plasma
and urine, which—according to the authors- could be a possible new marker for brain seroto-
nin synthesis in PKU patients [29]. As C57Bl/6 is one of many mouse strains being deficient in
melatonin [38], unfortunately, we were unable to correlate brain serotonin and plasma melato-
nin concentrations. Regarding the clinical importance of brain monoaminergic neurotransmit-
ters in PKU, traditionally, especially brain dopamine deficiency has been associated with
cognitive and mood disturbances in PKU [39,40]. However, brain norepinephrine impair-
ments may have been underestimated, while cerebral norepinephrine abnormalities have been
associated with many (neuro)psychiatric disorders [41].
Both insufficient precursor availability and impaired TH and TPH activity by inhibition of
excessive brain Phe concentrations have been hypothesized to account for the brain monoam-
inergic neurotransmitter deficits in PKU. The present results suggest that the relative contribu-
tion of each of these mechanisms may be different for the dopaminergic and serotoninergic
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pathways in PKU. Regarding the brain catecholamine deficiencies, the increased ratio of brain
dopamine/tyrosine and unaffected ratio of brain norepinephrine/tyrosine in PKU mice could
be explained in two ways, each supporting one of the two aforementioned main theories on
brain monoaminergic neurotransmitter deficiencies in PKU. Firstly, it may indicate that insuf-
ficient brain tyrosine availability rather than inhibition of TH by high Phe would be responsible
for the brain catecholamine deficiencies observed in PKU. This would support the report by
Fernstrom et al. (2007) concluding that increased brain Phe is not likely to impair catechol-
amine synthesis in PKU, whereas low brain tyrosine does [42]. In consequence, this would
implicate that even higher blood tyrosine concentrations may be needed to restore brain dopa-
mine concentrations. Secondly, the increased ratio of brain dopamine/tyrosine and unaffected
ratio of brain norepinephrine/tyrosine in PKU compared to WTmice on normal chow may be
explained by the fact that brain dopamine is not exclusively derived from brain tyrosine. This
would support the report by Ikeda et al. (1967) showing that TH, at least in vitro, could synthe-
size catecholamines also from Phe, which is abundant in the PKU brain. This would suggest
that insufficient precursor amino acid availability in brain would not be the primary mecha-
nism underlying reduced dopamine concentrations, but inhibition of TH by high Phe is [43].
In consequence, this would imply that further reduction of brain Phe concentrations would
probably be most effective to increase brain dopamine concentrations in PKU. Regarding the
observed serotonin deficits in PKU, the reduced ratios of brain serotonin/tryptophan in PKU
mice suggest that inhibition of TPH by high Phe does play an important role in the cerebral
serotonin impairments characterizing PKU. This is in good agreement with the in vitro obser-
vation that Phe inhibits TPH more strongly than TH [44]. To further discriminate between the
importance of both hypothesized mechanisms underlying brain monoaminergic neurotrans-
mitter impairments in PKU, future studies need to investigate the effects of selective brain tyro-
sine and tryptophan increase and selective brain Phe reduction on monoaminergic
neurotransmitter concentrations in PKU mice.
To conclude, this study was the first to investigate all hypothesized biochemical treatment
objectives of LNAA supplementation in PKU. Results in PKU mice showed that LNAA supple-
mentation improves brain biochemistry in PKU by three synergistic mechanisms. Thereby,
this study provides proof-of-concept for LNAA supplementation as a possible alternative treat-
ment strategy for PKU that improves brain biochemistry by targeting the unbalanced LNAA
transport across the BBB. Before clinical application should be considered, however, further
optimization of LNAA treatment with regard to the LNAA being supplemented and their dose
is required, taking into account all three brain biochemical treatment objectives.
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